The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
A PhD in Pharmaceutical Sciences, Dr Singh has led global regulatory audits, product validations, and quality systems spanning therapeutic formulations, dietary supplements, and functional foods
Company to launch product after the expiry of semaglutide patent in India
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced
The partnership initially will focus on cardiovascular and kidney diseases
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
Subscribe To Our Newsletter & Stay Updated
